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1. Introduction 
Hyperthermia is part of thermal medicine, in which increasing body or tissue temperature 
used for the treatment of diseases. It can be traced back to the earliest practice of medicine. 
Cultures from around the world can point to ancient uses of hot therapy for specific medical 
applications. As mentioned in the foregoing books, cauterization is the first application of 
hyperthermia in medicine. Cauterization can be done by heat, or by chemicals such as 
caustics. Al-Zahrawi - an ancient Arabic scientist- generally preferred the former for the use 
of cauterization in treatment of diseases (1). Depending on the nature of the disease, the 
patient's temperament and the weather condition, different kinds of metals such as bronze, 
iron and gold could be used. The important considerations in the procedure include the 
shape of the cautery, the site of cauterization and the number of exposures. Many of the 
cauteries were taken from the Greeks, but Al-Zahrawi takes an independent line while 
describing cauterization for hare-lip, entropion, pulmonary disease, pre-anal fistula, 
dislocation of femur, back pain, headache, ptosis, perianal fistulae, humeral dislocation, 
sciatica and face swellings (fig 1). 
Modern research in thermal medicine aims to understand molecular, cellular and 
physiological effects of temperature manipulation and the “stress” response, as well as to 
develop effective and safe equipment for clinical application and temperature monitoring. 
As a result, today there are a growing number of clinical applications of thermal therapy 
that benefit patients with a variety of diseases. Remarkable progress in engineering, 
radiology and physics over the past decades has led to the implementation of clinical trials 
that are revealing the true potential of hyperthermia for the treatment of different disease. 
Hyperthermia ablation (e.g. by radiofrequency electric current, microwaves, laser, or 
ultrasound), whereby localized heating destroys tissue is now used worldwide for tumors 
treatment and many other important medical applications. In most circumstances thermal 
ablation is used under guidance of different radiological modalities such as ultrasound (US), 
computed tomography (CT) or magnetic resonance imaging (MRI). Thermal ablation is a  
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Figure 1. Technique of Cauterization by fire for a patient with neck swelling (1) 
minimally invasive procedure that significantly reduces risks and speeds recovery. So, it 
provides an excellent safe alternative to major surgery. The primary advantage of 
percutaneous radiofrequency thermal ablation is a reduction in the need for post-operative 
hospitalization and a reduced duration of convalescence. In this chapter, we will review the 
recent application of hyperthermia medicine in treatment of different disease under the 
guidance of different radiological modalities. In this chapter, we will provide a clearer 
picture of the intimate relation between hyperthermia, radiology and medical imaging. We 
will discuss the multiple facets of tumor growth and the tumor microenvironment that can 
be impacted by heat during hyperthermia medicine. We will emphasize the approved 
clinical application of hyperthermia in management of growing number of patients with a 
variety of diseases. We also discuss other experimental and investigational trial studies that 
can be used effectively in the future for management of other clinical conditions. Also we 
will emphasize the adjuvant role of thermal therapy in combination with radiotherapy and 
chemotherapy in management of cancer. Finally, we will elaborate the exciting new 
generation of clinical trials of heat-activated drug delivery.  
2. Various energy sources of hyperthermia 
Various energy sources including laser, ultrasound, microwaves, and radiofrequency 
electric current are being investigated as minimally invasive, and potentially non-invasive 
therapies. There are two types of thermal ablation: radiofrequency (RFA) and microwave. 
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Both are minimally invasive techniques that treat lesions by applying intense heat through a 
small probe inserted directly into the tumor. Hyperthermia can be either superficial, 
produced by a microwave generator, or regional, produced by a radiofrequency applicator 
with multiple antennas, which emanate a deep focalized heating, saving the skin, or 
interstitial heating. In all these systems the radiations are non-ionizing, in which the energy 
presents a heterogeneous distribution inside the tissues, depending on their thermal 
characteristics and on blood perfusion. Radiofrequency ablation (RFA) involves 
percutaneous or intra-operative insertion of an electrode into a lesion under ultrasonic or CT 
guidance. Radiofrequency energy is emitted through the electrode and generates heat, 
leading to coagulative necrosis of the tissue.  
3. Rational of tissue necrosis (ablation) in hyperthermia medicine 
Modern research in thermal medicine aims to understand molecular, cellular and 
physiological effects of temperature manipulation and the “stress” response, as well as to 
develop effective and safe equipment for clinical application and temperature monitoring. 
Multiple facets of tumor growth and the tumor microenvironment, including vascular 
perfusion, heat shock protein expression, endothelial/stromal cells, hypoxia, immune cells, 
pro-inflammatory cytokines, are impacted by heat and these effects may underlie 
remarkable successes being obtained in a surge of clinical trials throughout the world. 
Thermal ablation whereby tissue is destroyed by localized heating or freezing, is now used 
worldwide for treatment of many benign and malignant tumors and several other important 
medical applications (2-4). 
The main actions of hyperthermia in the neoplastic tissues are the following: 
 Greater heat sensitivity of neoplastic tissues to hyperthermia, due to its chronic 
ischemia, hypoxia and acid pH; 
 Lethal effect of temperature of 42-43 °C on tumor cells, depending on the application time; 
 Temporary growth stabilization of tumor cells after a moderate hyperthermia (39-41 
°C); 
 Prolonged action of temperature, due to lower thermal dissipation, caused by a chronic 
ischemia inside the tumor, as a result of its reduced vessel regulation mechanisms; 
 Alterations in the neoplastic cell cycle, which lead to the blocking of mitosis, due to a 
disruption in the S phase; 
 Marked action on the core of the tumor, less sensitive to radiation because of ischemia, 
hypoxia and low pH; 
 action in favor of apoptosis mechanisms. 
4. Common clinical application of hyperthermia therapy: 
Today there are a growing number of clinical applications of thermal therapy that benefit 
patients with a variety of diseases. Several studies have been published reporting efficacy of 
RFA in treatment of many different clinical conditions.  
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Several studies have been published reporting successful use of radiofrequency ablation in 
the following conditions: as an alternative to surgical resection for debulking of primary and 
metastatic malignant neoplasms, removal of primary or metastatic malignant neoplasms, 
treatment of distant metastases of medullary thyroid carcinoma, treatment of metastatic 
gastrointestinal stromal tumors (GIST) with limited progression, treatment of osteoid 
osteoma, as a less invasive alternative to surgical resection of the tumor ,treatment of soft 
tissue sarcoma of the trunk or extremities in symptomatic persons with disseminated 
metastases and many other condition. 
There is growing research and experimental and investigational studies interest in the use of 
hyperthermia for treatment of many other clinical conditions. But these studies need to 
improve its clinical outcomes to be implemented in the practical life. Examples of these 
studies include; curative treatment of primary or metastatic malignant neoplasms (e.g., 
breast cancer, kidney cancer including renal angiomyolipoma, lung cancer, and pancreatic 
cancer) in persons who are able to tolerate surgical resection, treatment of malignant bile 
duct obstruction due to insufficient evidence in the peer-reviewed literature. Treatment of 
Barrett's esophagus, treatment of hepatic tumors, treatment of benign prostatic hypertrophy 
(transurethral needle ablation or TUNA) ,cardiac catheter thermal ablation is now standard 
of care for a variety of cardiac arrhythmia types (irregular heart beat rhythm) ,endometrial 
ablation is clinically used to treat endometrial bleeding ,intravascular heating can eliminate 
varicose veins with laser or radiofrequency current, laser and other thermal methods treat 
excessive subcutaneous fat, which can contribute to obesity and metabolic disorders 
including diabetes. Hyperthermia can also be used to activate cytotoxic effects of 
chemotherapy within tumors, thereby sparing normal tissue, when the drugs are 
encapsulated in thermally sensitive nanoparticles. As a result of these and other clinical 
applications, combined with a rapidly expanding research base, interest in thermal medicine 
is rapidly growing, attracting the attention of laboratory and clinical researchers, physicians, 
engineers, physicists and biotechnologists  
4.1. Radiofrequency ablation of osteoid osteoma 
Osteoid osteoma, a benign tumor of the bone. It is the third most common primary benign 
bone tumor, representing approximately 10–12% of benign bone tumors . It generally affects 
children and young adults. Approximately 80% of patients are between 5 and 24 years of 
age, with a male: female ratio of 3:1. Clinically, pain is the most common presenting 
symptom and is described as severe, sharp, boring, and typically worse at night, and 
improves with nonsteroidal anti-inflammatory drugs [5]. The growth potential of these 
benign lesions is limited, with a maximum diameter rarely exceeding 15 mm. However, the 
inflammatory response leads to the characteristic severe pain. The consequences of these 
lesions include growth deformities when tumors are located in the long bones and scoliosis 
when the posterior elements of the spine are involved [6]. Patients who cannot tolerate the 
symptoms or nonsteroidal anti-inflammatory drugs require intervention for pain relief 
and/or to prevent growth disturbance. Traditionally, surgical resection was the treatment of 
choice. During open surgery the nidus of the tumor is often difficult to visualize and to 
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prevent recurrence a wide resection margin may be required. This results in many 
complications such as hematoma, infection, and fracture. In addition, surgical treatment 
may require a long period of hospitalization, a period during which the patient cannot bear 
weight on the affected limb resulting in delayed resumption of physical activity [7]. The 
optimal method of treatment for osteoid osteoma would involve minimization of bone 
removal with avoidance of grafting and fixation while ensuring complete destruction of the 
tumor nidus in a single session. During the past two decades, many attempts have been 
made to minimize bone removal to decrease the risk of postoperative complications. 
Percutaneous resection utilizing CT guidance to guide trephines and drills has been 
described. However, the complication rates are as high as 24% and include fractures, 
muscular haematomas, paraesthesia, skin burns, transient paresis, and osteomyelitis [8]. 
Radiofrequency ablation has proved to be an effective method for the treatment of many 
malignant and benign tumors. RF ablation for the treatment of osteoid osteoma was first 
described in a four-patient series in 1992 [9]. Since the promising results of Rosenthal et al in 
the management of osteoid osteoma with RF ablation a large number of studies evaluating 
RF ablation of osteoid osteoma have been reported in the peer-reviewed medical literature. 
Most of these studies found very high technical success rates (100%) and good primary 
success rates with a single session of ablation ranging from 76% to 100% (fig 2 and fig 3). 
Today, percutaneous CT-guided RF ablation is an effective and safe minimally invasive 
procedure for the treatment of osteoid osteoma in all ages. It has high technical and clinical 
success rates (10-12) 
 
Figure 2. Technique of RFA of osteoid osteoma in a 12-year-boy with chronic right hip pain. a 
Radiograph of the pelvis shows an ill-defined area of dense sclerosis in the medial aspect of the 
proximal femoral shaft (arrow). b Bone scan shows active uptake at the site of the dense sclerosis 
consistent with the diagnosis of osteoid osteoma. c CT scan shows the nidus located deep to the cortex 
and surrounded by dense new bone. The radiopaque markers on the skin surface are for planning the 
skin entry point. d Axial 1-mm CT slice shows the correct position of the tip of the RF electrode within 
the centre of the nidus. e Follow-up CT after 15 months shows sclerosis within the nidus (12) 
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Figure 3. RFA of osteoid osteoma in a 14-year-old girl. a MR images shows a small, well-defined lesion 
in the proximal tibial epiphysis. b CT during percutaneous RF ablation shows a radiolucent nidus with 
central calcification surrounded by a dense rim of sclerosis. Note markers for planning the skin entry 
point. c CT shows the bone biopsy probe tip at the margin of the nidus . d CT shows the tip of the RF 
electrode within the nidus after slight withdrawal of the penetrating cannula. e Control image obtained 
immediately after the intervention shows the biopsy tract with no bleeding(12) 
4.2. Radiofrequency ablation of pulmonary tumors 
Radiofrequency ablation has been advocated as an alternative to resection in persons with 
lung nodules who cannot be treated surgically because of medical problems, multiple 
tumors, or poor surgical risk. There are, however, no adequate prospective clinical studies 
that demonstrate that RFA of lung metastases is as effective as surgical (cold knife) resection 
in curative resection of malignant neoplasms. An important concern is that RFA does not 
allow for examination of surgical margins to ensure that cancer is completely resected. Le 
and Petrik considered RFA as a promising technique for the treatment of early states (state I 
and stage II) non-small cell lung cancer (13). An assessment by the National Institute for 
Health and Clinical Excellence (NICE, 2006) concluded: "Current evidence on the safety and 
efficacy of percutaneous radiofrequency ablation for primary and secondary lung cancers 
shows that there are no major safety concerns with this procedure. There is evidence that the 
treatment can reduce tumor bulk; however, this evidence is limited and is based on 
heterogeneous indications for treatment. The procedure should therefore be used only with 
special arrangements for consent, audit and clinical governance (14). “The Food and Drug 
Administration (FDA) has issued a Public Health Notification as clarification for healthcare 
providers that no RFA devices are specifically approved for use in partial or full ablation of 
lung tumors (15). Radiofrequency ablation devices are minimally invasive tools used for 
general removal of soft tissue, such as those that contain cancer cells. It is an image-guided 
technique that heats and destroys cancer cells. Imaging techniques such as ultrasound and 
computed tomography (CT) are used to help guide a needle electrode into a cancerous 
tumor. High-frequency electrical currents are then passed through the electrode, creating 
heat that destroys the abnormal cells. 
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4.3. Radiofrequency ablation of pancreatic cancer 
Radiofrequency ablation has been used as a treatment of pancreatic cancer for a number of 
years in Japan. Current evidence of effectiveness of RFA for pancreatic cancer consists of 
case reports and a phase II (safety) study; the latter concluded that RFA was a relatively safe 
treatment for pancreatic cancer. However, this evidence is insufficient to draw conclusions 
about the effectiveness of RFA for this indication. Girelli et al (2010) examined the feasibility 
and safety of RFA as a treatment option for locally advanced pancreatic cancer. A total of 50 
patients with locally advanced pancreatic cancer were studied prospectively. Ultrasound-
guided RFA was performed during laparotomy. The main outcome measures were short-
term morbidity and mortality. The tumor was located in the pancreatic head or uncinate 
process in 34 patients and in the body or tail in 16; median diameter was 40 (inter-quartile 
range [IQR] of 30 to 50) mm. Radiofrequency ablation was the only treatment in 19 patients; 
it was combined with biliary and gastric bypass in 19 patients, gastric bypass alone in 8, 
biliary bypass alone in 3 and pancreatico-jejunostomy in 1. The 30-day mortality rate was 2 
%. Abdominal complications occurred in 24 % of patients; in half they were directly 
associated with RFA and treated conservatively. Three patients with surgery-related 
complications needed re-operation. Reduction of RFA temperature from 105 degrees C to 90 
degrees C resulted in a significant reduction in complications (10 versus 2 of 25 patients; p = 
0.028). Median post-operative hospital stay was 10 (range of 7 to 31) days. The authors 
concluded that RFA of locally advanced pancreatic cancer is feasible and relatively well 
tolerated, with a 24 % complication rate. This was a feasibility and safety study; it did not 
provide any data on the effectiveness of RFA in treating pancreatic cancer (16). 
4.4. Radiofrequency ablation of renal tumors 
Several authorities have noted that RFA of renal tumors is a promising investigational 
alternative to partial or total nephrectomy. Studies performed have focused on the technical 
feasibility of RFA of renal tumors. Prospective clinical studies are needed to determine if 
RFA of renal cell carcinomas improve survival and are as effective as total or partial 
nephrectomy (17-18) 
An assessment conducted by the National Institute for Clinical Excellence in 2010 reached 
the following conclusions about RFA of renal tumors: " A meta-analysis of 47 studies (non-
randomized comparative studies and case series) including a total of 1375 tumors treated by 
RFA (n = 775) or cryoablation (n = 600) reported local tumor progression (defined as 
radiographic or pathological evidence of residual disease after initial treatment, regardless 
of time to recurrence) in 13% (100/775) and 5% (31/600) of tumors respectively at a mean 19-
month follow-up (p < 0.001). The meta-analysis reported progression to metastatic disease in 
2% (19/775) of tumors treated by RFA and 1% (6/600) of tumors treated by cryoablation(p = 
not significant)" (19). Another assessment of the evidence for RFA of kidney cancer prepared 
by the Canadian Coordinating Office for Health Technology Assessment (20) reached the 
following conclusions: "RFA is emerging as a useful alternative to nephrectomy in the 
management of some types of kidney cancer. It appears to be useful for smaller, non-central 
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tumors, and for cases where surgery is contraindicated. A disadvantage is the possibility of 
residual cancer that cannot be detected by diagnostic imaging during follow-up. There are 
no results from randomized trials, and the period of follow-up for patients who have had 
the procedure is short. Only with longer follow-up evaluations (five years to 10 years) will 
relevant comparison with radical and partial nephrectomy be possible." 
Furthermore, Hinshaw and Lee stated that RFA, cryoablation, microwave ablation, and laser 
ablation have all shown promise for the treatment of renal cell carcinomas (RCC), with high 
local control and low complication rates for RFA and cryoablation. However, the clinical 
trial data remain early, and survival data are not yet available for a definitive comparison 
with conventional surgical techniques for removal of RCC (21). Mahnken noted that the 
increasing number of clinical reports on RFA of the kidney show the promising potential of 
renal RFA for minimally invasive tumor treatment. Due to its technical benefits, RFA seems 
to be advantageous when compared to cryoablation or laser ablation. However, there are no 
long-term follow-up or comparative data proving an equal effectiveness to surgery (22) . 
In a systematic review on focal therapy for kidney cancer, Kutikov and colleagues stated that 
most cryoablations are performed using a laparoscopic approach, whereas RFA of the 
localized small renal masses (SRM) is more commonly administered percutaneously. Pre-
treatment biopsy is performed more often for lesions treated by cryoablation than RFA with a 
significantly higher rate of indeterminate or unknown pathology for SRMs undergoing RFA 
versus cryoablation (p < 0.0001). Currently available data suggest that cryoablation results in 
lower re-treatments (p < 0.0001), less local tumor progressions (p < 0.0001) and may be 
associated with a decreased risk of metastatic progression compared with RFA. It is unclear if 
these differences are a function of the technologies or their application. The extent to which 
focal ablation altars the natural history of SRMs has not yet been established. The authors 
concluded that currently, data on the ability of interventions for SRMs to affect the natural 
history of these masses are lacking. They stated that prospective randomized evaluations of 
available clinical approaches to SRMs are needed (23). A Cochrane systematic evidence 
review (24) of surgical management of localized renal cell carcinoma found that the main 
source of evidence for the current practice of laparoscopic excision of renal cancer is drawn 
from case series, small retrospective studies and very few small-randomized controlled trials. 
"The results and conclusions of these studies must therefore be interpreted with caution." The 
authors of the systematic evidence review did not identify any randomized trials meeting the 
inclusion criteria reporting on the comparison between open radical nephrectomy with 
laparoscopic approach or new modalities of treatment such as RFA or cryoablation. Three 
randomized controlled trials compared the different laparoscopic approaches to 
nephrectomy (transperitoneal versus retroperitoneal) and found no statistical difference in 
operative or peri-operative outcomes between the two treatment groups. There were several 
non-randomized and retrospective case series reporting various advantages of laparoscopic 
renal cancer surgery such as less blood loss, early recovery and shorter hospital stay. 
Sooriakumaran and co-workers examined the presentation, management and outcomes of 
patients with renal angiomyolipoma (AML) over a period of 10 years. These investigators 
evaluated retrospectively 102 patients (median follow-up of 4 years); 70 had tuberous 
 
Hyperthermia and Radiology 153 
sclerosis complex (TSC; median tumor size of 3.5 cm) and the other 32 were sporadic 
(median tumor size of 1.2 cm). Data were gathered from several sources, including 
radiology and clinical genetics databases. The 77 patients with stable disease were followed-
up with surveillance imaging, and 25 received interventions, some more than one. 
Indications for intervention included spontaneous life-threatening hemorrhage, large AML 
(10 to 20 cm), pain and visceral compressive symptoms. Selective arterial embolization 
(SAE) was performed in 19 patients; 10 received operative management and 4 had a RFA. 
Selective arterial embolization was effective in controlling hemorrhage from AMLs in the 
acute setting (n = 6) but some patients required further intervention (n = 4) and there was a 
significant complication rate. The reduction in tumor volume was only modest (28 %). No 
complications occurred after surgery (median follow-up of 5.5 years) or RFA (median 
follow-up of 9 months). One patient was entered into a trial and treated with sirolimus 
(rapamycin). The authors concluded that the management of AML is both complex and 
challenging, especially in those with TSC, where tumors are usually larger and multiple. 
Although SAE was effective at controlling hemorrhage in the acute setting it was deemed to 
be of limited value in the longer-term management of these tumors. Thus, novel techniques 
such as focused ablation and pharmacotherapies including the use of anti-angiogenic 
molecules and mammalian target of rapamycin inhibitors, which might prove to be safer 
and equally effective, should be further explored (25). 
4.5. Radiofrequency ablation of bone metastases 
Radiofrequency ablation has also been used to treat bone metastases. However, there are no 
adequate clinical studies reported in the literature on the use of RFA of metastatic lesions to 
bone. In a review of the evidence on RFA of tumors, Wood et al concluded “more rigorous 
scientific review, long-term follow-up, and randomized prospective trials are needed to help 
define the role of RFA in oncology” (26). Rhim noted that although RFA represents a 
paradigm shift in local therapy for many commonly seen tumors, more sophisticated 
strategies to enhance the therapeutic effectiveness are needed and more randomized, 
controlled trials to estimate its clinical benefit are warranted (27).  
4.6. Radiofrequency ablation of breast cancer 
On of the first attempt to use hyperthermia in tratment of breast cancer was in 2001 by Hilger 
et al (28). They studied the parameters for the minimally invasive elimination of breast tumors 
by using a selective application of magnetite and exposure of the breast to an alternating 
magnetic field. Temperature elevations based on magnetite mass (7–112 mg) and magnetic 
field amplitude (1.2–6.5 kA/m; frequency, 400 kHz) . They observed that a mean temperature 
of 71°C ± 8 was recorded in the tumor region at the end of magnetic field exposure of the mice. 
Typical macroscopic findings included tumor shrinkage after heating. Histologically nuclear 
degenerations were observed in heated malignant cells. They concluded that magnetic heating 
of breast tumors is a promising technique for future interventional radiologic treatments. 
Agnese and Burak stated that ablative therapies, including RFA have been shown promise in 
the treatment of small cancers of the breast. However, more research is needed to ascertain the 
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effectiveness of these techniques when they are used as the sole therapy and to determine the 
long-term local recurrence rates and survival associated with these treatment strategies (29). 
van der Ploeg et al in 2007 reviewed the literature on the use of RFA for the treatment of small 
breast carcinoma. The authors concluded that RFA is a promising new tool for minimally 
invasive ablation of small carcinomas of the breast. They noted that a large randomized 
control study is needed to ascertain the long-term advantages of RFA compared to the current 
breast conserving therapies (30). 
4.7. Radiofrequency ablation of a parathyroid adenoma 
One of the methods of nonsurgical parathyroid ablation is percutaneous thermal ablation, 
such as laser or radiofrequency ablation. Percutaneous laser and radiofrequency ablation of 
parathyroid adenomas has been limited to case reports and small-series cases [31–32]. The 
ultimate utility of thermal ablation has yet to be determined but because it continues to be 
refined, it does hold promise as a method for treatment of parathyroid disease when surgery 
is not indicated. RFA can be a therapeutic alternative for patients with contraindications for 
surgery. Usually after percutaneous ultrasound guided RFTA of the adenoma of the 
parathyroid gland, the serum parathormone levels and the serum calcium levels dropped 
back to normal in most of patients (fig 4). Recurrent hyperparathyroidism is rare following 
transcatheter ablation of mediastinal parathyroid adenomas. When it occurs it is usually 
early and resistant to further attempts at ablation (33) 
 
Figure 4. Radiofrequency ablation of parathyroid adenoma .A, Transverse sonogram of neck shows 
15x10-mm right inferior parathyroid adenoma (PTA) .B; Sonogram of the neck after inflation of 5 ml 
saline (white arrow) to separate the PTA from the right common carotid artery (CCA). C ; Sonogram 
shows 25-gauge needle (arrows) inserted into parathyroid adenoma . D; Sonogram shows fans (arrows) 
of the radiofrequency probe within the PTA . E ; Sonogram during RFA of PTA shows reverberation 
artifacts (arrows) posterior to the needle) . F; Sonogram at the total RFA of the PTA, The ablated gland 
(arrows) appears echogenic. 
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4.8. RFA in management of Barrett's esophagus 
Barrett's esophagus (BE) is defined as the presence of specialized intestinal metaplasia 
within the esophagus, and it is the pre-malignant precursor of esophageal adenocarcinoma. 
Esophageal cancer is one of the most deadly gastrointestinal cancers with a mortality rate 
over 90 %. The principal risk factors for esophageal adenocarcinoma are gastroesophageal 
reflux disease (GERD) and its sequela, BE. Gastroesophageal reflux disease usually leads to 
esophagitis. However, in a minority of patients, ongoing GERD leads to replacement of 
esophageal squamous mucosa with metaplastic, intestinal-type Barrett's mucosa. In the 
setting of continued peptic injury, Barrett's mucosa can give rise to esophageal 
adenocarcinoma (34). A new method of endoscopic ablation of BE is balloon-based, bipolar 
RFA (Stellartech Research Coagulation System; BARRx, Inc, Sunnyvale, Calif), also known 
as Barrett's endoscopy. This technique requires the use of sizing balloons to determine the 
inner diameter of the targeted portion of the esophagus. This is followed by placement of a 
balloon-based electrode with a 3-cm long treatment area that incorporates tightly spaced, 
bipolar electrodes that alternate in polarity. The electrode is then attached to a 
radiofrequency generator and a preselected amount of energy is delivered in less than 1 
second at 350 W. In a review of evidence on ablative techniques for BE, Johnston stated that 
it is not clear which of the numerous endoscopic ablative techniques available -- 
photodynamic therapy, laser therapy, multi-polar electrocoagulation, argon plasma 
coagulation, endoscopic mucosal resection, RFA or cryotherapy -- will emerge as superior 
for treatment of BE. In addition, it has yet to be determined whether the risks associated 
with ablation therapy is less than the risk of BE progressing to cancer. Whether ablation 
therapy eliminates or significantly reduces the risk of cancer, eliminates the need for 
surveillance endoscopy, or is cost-effective, also remains to be seen. Comparative trials that 
are now underway should help to answer these questions (35). Hubbard and Velanovich 
stated that endoscopic endoluminal RFA using the Barrx device (Barrx Medical, Sunnyvale, 
CA) is a new technique to treat BE. This procedure has been used in patients who have not 
had anti-reflux surgery. This report presented an early experience of the effects of 
endoluminal ablation on the reflux symptoms and completeness of ablation in post-
fundoplication patients. A total of 7 patients who have had either a laparoscopic or open 
Nissen fundoplication and BE underwent endoscopic endoluminal ablation of the Barrett's 
metaplasia using the Barrx device. Pre-procedure, none of the patients had significant 
symptoms related to GERD. One to 2 weeks after the ablation, patients were questioned as 
to the presence of symptoms. Pre-procedure and post-procedure, they completed the GERD-
HRQL symptom severity questionnaire (best possible score, 0; worst possible score, 50). 
Patients had follow-up endoscopy to assess completeness of ablation 3 months after the 
original treatment. All patients completed the ablation without complications. No patients 
reported recurrence of their GERD symptoms. The median pre-procedure total GERD-
HRQL score was 2, compared to a median post-procedure score of 1. One patient had 
residual Barrett's metaplasia at 3 months follow-up, requiring re-ablation. The authors 
concluded that this preliminary report of a small number of patients demonstrated that 
endoscopic endoluminal ablation of Barrett's metaplasia using the Barrx device is safe and 
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effective in patients who have already undergone anti-reflux surgery. There appears to be 
no disruption in the fundoplication or recurrence of GERD-related symptoms. Nevertheless, 
they stated that studies with longer-term follow-up and with more patients are needed (36). 
Ganz et al evaluated the safety and effectiveness of endoscopic circumferential balloon-
based ablation by using radiofrequency energy for treating BE that contains high-grade 
dysplasia (HGD). Patients with histologic evidence of intestinal metaplasia (IM) that 
contained HGD confirmed by at least 2 expert pathologists were included in this study. A 
prior endoscopic mucosal resection (EMR) was permitted, provided that residual HGD 
remained in the BE region for ablation. Histologic complete response (CR) end points: (i) all 
biopsy specimen fragments obtained at the last biopsy session were negative for HGD (CR-
HGD), (ii) all biopsy specimens were negative for any dysplasia (CR-D), and (iii) all biopsy 
specimens were negative for IM (CR-IM). A total of 142 patients (median age of 66 years, 
IQR 59 to 75 years) who had BE HGD (median length of 6 cm, IQR 3 to 8 cm) underwent 
circumferential ablation (median of 1 session, IQR 1 to 2 sessions). No serious adverse 
events were reported. There was 1 asymptomatic stricture and no buried glands. Ninety-
two patients had at least 1 follow-up biopsy session (median follow-up of 12 months, IQR 8 
to 15 months). A CR-HGD was achieved in 90.2 % of patients, CR-D in 80.4 %, and CR-IM in 
54.3 %. The authors concluded that endoscopic circumferential ablation is a promising 
modality for the treatment of BE that contains HGD. In this multi-center registry, the 
intervention safely achieved a CR for HGD in 90.2 % of patients at a median of 12 months of 
follow-up. Major drawbacks of this study were a non-randomized study design, absence of 
a control arm, a lack of centralized pathology review, ablation and biopsy technique not 
standardized, and a relatively short-term follow-up (37) .  
Shaheen et al examined if endoscopic RFA could eradicate dysplastic BE and decrease the 
rate of neoplastic progression. In a multi-center, sham-controlled trial, these researchers 
randomly assigned 127 patients with dysplastic BE in a 2:1 ratio to receive either RFA 
(ablation group) or a sham procedure (control group). Randomization was stratified 
according to the grade of dysplasia and the length of BE. Primary outcomes at 12 months 
included the complete eradication of dysplasia and intestinal metaplasia. In the intention-to-
treat analyses, among patients with low-grade dysplasia, complete eradication of dysplasia 
occurred in 90.5 % of those in the ablation group, as compared with 22.7 % of those in the 
control group (p < 0.001). Among patients with high-grade dysplasia, complete eradication 
occurred in 81.0 % of those in the ablation group, as compared with 19.0 % of those in the 
control group (p < 0.001). Overall, 77.4 % of patients in the ablation group had complete 
eradication of intestinal metaplasia, as compared with 2.3 % of those in the control group (p 
< 0.001). Patients in the ablation group had less disease progression (3.6 % versus 16.3 %, p = 
0.03) and fewer cancers (1.2 % versus 9.3 %, p = 0.045). Patients reported having more chest 
pain after the ablation procedure than after the sham procedure. In the ablation group, 1 
patient had upper gastrointestinal hemorrhage, and 5 patients (6.0 %) had esophageal 
stricture. The authors concluded that in patients with dysplastic BE, RFA was associated 
with a high rate of complete eradication of both dysplasia and intestinal metaplasia and a 
reduced risk of disease progression (38). As stated by the authors, this study has several 
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limitations: (i) these investigators used eradication of intestinal metaplasia and dysplasia, 
along with neoplastic progression, as surrogate markers for death from cancer, even though 
long-term data demonstrating an association between eradication of intestinal metaplasia 
and a decreased risk of cancer are sparse, (ii) the study duration was 1 year. Although other 
data suggest that reversion to neosquamous epithelium after RFA is durable, it is unclear if 
the results of the study will persist, (iii) because of stratified randomization according to the 
degree of dysplasia and the 2:1 ratio for assignment of patients to the ablation group and the 
control group, the number of patients in some groups was small, (iv) since this study did not 
compare RFA with other interventions, such as photodynamic therapy and esophagectomy, 
these researchers can not determine which of these interventions is superior, (v) whether 
these findings can be generalized to community-practice settings is unknown. Furthermore, 
the risk of subsquamous intestinal metaplasia following ablative therapy is a concern for all 
ablative techniques. However, the malignant potential of subsquamous intestinal metaplasia 
is unknown. In this study, subsquamous intestinal metaplasia was quite common in patients 
(25.2 %) before enrollment and, similar to previous reports, was low after RF ablation (5.1 
%). Although the biopsy regimen in this study was aggressive, it is possible that some 
patients had undetected subsquamous intestinal metaplasia. Finally, because these 
investigators sought to define the efficacy of RFA for the spectrum of dysplasia, they 
enrolled patients with both low-grade dysplasia and high-grade dysplasia. However, the 
implications of these 2 diagnoses are markedly different. Low-grade dysplasia implies a risk 
of progression to cancer of less than 1 % per patient-year, whereas the risk associated with 
high-grade dysplasia may be higher by a factor of 10. In making decisions about the 
management of pre-cancerous conditions, clinicians, patients, and policy-makers consider 
possible benefits and risks of competing strategies. Because high-grade dysplasia has a more 
ominous natural history than low-grade dysplasia (or non-dysplastic intestinal metaplasia), 
greater risks and costs are tolerable. For less severe disease, the safety profile and associated 
costs become increasingly important. Detailed consideration of these trade-offs is beyond 
the scope of this study. Regardless, both of the dysplasia subgroups showed high rates of 
reversion to squamous epithelium after RFA and reduced rates of disease progression with 
few serious adverse effects, suggesting that the application of ablative therapy in patients 
with low-grade dysplasia is worth further investigation and consideration (38). 
In the accompanying editorial, Bergman stated that it is still too early to promote RFA for 
patients with non-dysplastic BE. Dr. Bergman also asked the following questions: (i) is 
complete response after ablation maintained over time, thus reducing the risk of progression 
to high-grade dysplasia or cancer?, (ii) will ablation improve patients' quality of life and 
decrease costs, as compared with the surveillance strategy?, and (iii) can we define a 
stratification index predicting disease progression or response to therapy? The author noted 
that "[w]e run the risk of losing the momentum to enroll patients in a trial that is required at 
this stage: a randomized comparison of endoscopic surveillance and radiofrequency 
ablation for non-dysplastic Barrett's esophagus. Such a study might truly revolutionize the 
management of this condition and answer the question as to whether radiofrequency 
ablation is great just for some or justified for many" (39). Furthermore, the American College 
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of Gastroenterology's updated guidelines for the diagnosis, surveillance and therapy of BE , 
Wang and Sampliner states that "further evaluation of the most recent technology; 
radiofrequency ablation is awaited. Cryotherapy is beginning clinical trials and older 
technologies are becoming more refined (e.g., photodynamic therapy with the development 
of new agents). Documentation of the frequency and duration of the surveillance protocol 
after endoscopic ablation therapy requires careful study" (40). 
4.9. RFA of esophageal neoplasm 
Yeh and Triadafilopoulos noted that a wide variety of endoscopic mucosal ablative 
techniques have been developed for early esophageal neoplasia. However, long-term 
control of neoplasic risk has not been demonstrated. The authors explained that most 
studies show that specialized intestinal metaplasia may persist underneath neo-squamous 
mucosa, posing a risk for subsequent neoplastic progression (41). Shaheen noted that the 
pathogenesis of BE is poorly understood. Given that some patients will have repeated bouts 
of severe erosive esophagitis and never develop BE, host factors must play an important 
role. The author stated that the utility of neoadjuvant radiation and chemotherapy in those 
with adenocarcinoma, although they are widely practiced, is not of clear benefit, and some 
authorities recommend against it. Ablative therapies, as well as endoscopic mucosal 
resection, hold promise for those with superficial cancer or high-grade dysplasia. The author 
noted that most series using these modalities feature relatively short follow-up; longer-term 
studies are needed to better ascertain the effectiveness of these treatments (38).  
Pedrazzani et al evaluated the effectiveness of 90 W argon plasma coagulation (APC) for the 
ablation of BE that is considered to be the main risk factor for the development of 
esophageal adenocarcinoma. They found that high power setting APC showed to be safe. 
The effects persist at a mean follow-up period of 2 years with a comparable cost in term of 
complications with respect to standard power settings. The authors stated, however, that 
further studies with greater number of patients are required to confirm these results and to 
assess if ablation reduces the incidence of malignant progression (42). Hage et al stated that 
although endoscopic removal of BE by ablative therapies is possible in the majority of 
patients, histologically complete elimination can not be achieved in all cases. Persistent BE 
may still harbor molecular aberrations and must therefore be considered still to be at risk of 
progression to adenocarcinoma (43). 
4.10. RFA of thyroid metastasis 
Guidelines on thyroid cancer from the National Comprehensive Cancer Network (NCCN, 
2010) state that distant metastases from recurrent or persistent medullary thyroid carcinoma 
that are causing symptoms (e.g., those in bone) could be considered for palliative resection, 
RFA, or other regional treatment. The guidelines state that these interventions may also be 
considered for asymptomatic distant metastases (especially for progressive disease) but 
observation is acceptable, given the lack of data regarding alteration in outcome (44). 
Monchik and colleagues evaluated the long-term effectiveness of RFA and percutaneous 
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ethanol (EtOH) injection treatment of patients with local recurrence or focal distant 
metastases of well-differentiated thyroid cancer (WTC). A total of 20 patients underwent 
treatment of biopsy-proven recurrent WTC in the neck. Sixteen of these patients had lesions 
treated by ultrasound-guided RFA (mean size, 17.0 mm; range of 8 to 40 mm), while 6 had 
ultrasound-guided EtOH injection treatment (mean size, 11.4 mm; range of 6 to 15 mm). 
Four patients underwent RFA treatment of focal distant metastases from WTC. Three of 
these patients had CT-guided RFA of bone metastases (mean size, 40.0 mm; range of 30 to 60 
mm), and 1 patient underwent RFA for a solitary lung metastasis (size, 27 mm). Patients 
were then followed with routine ultrasound, whole body scan, and/or serum thyroglobulin 
levels for recurrence at the treatment site. No recurrent disease was detected at the 
treatment site in 14 of the 16 patients treated with RFA and in all 6 patients treated with 
EtOH injection at a mean follow-up of 40.7 and 18.7 months, respectively. Two of the 3 
patients treated for bone metastases were disease-free at the treatment site at 44 and 53 
months of follow-up, respectively. The patient who underwent RFA for a solitary lung 
metastasis was disease-free at the treatment site at 10 months of follow-up. No 
complications were experienced in the group treated by EtOH injection, while 1 minor skin 
burn and 1 permanent vocal cord paralysis occurred in the RFA treatment group. The 
authors concluded that RFA and EtOH ablation show promise as alternatives to surgical 
treatment of recurrent WTC in patients with difficult reoperations. They stated that further 
long-term follow-up studies are needed to ascertain the precise role these therapies should 
play in the treatment of recurrent WTC (45). 
4.11. RFA of Soft tissue masses 
Radiofrequency ablation devices have been cleared by the FDA for the general indication of 
soft tissue cutting, coagulation, and ablation by thermal coagulation necrosis. This clearance 
was based only on bench testing or animal testing performance data. Guidelines from the 
National Comprehensive Cancer Network (NCCN, 2010) include recommendations for RFA 
of the trunk and extremities in metastatic soft tissue sarcoma. The guidelines include 
metastasectomy with RFA as an alternative method for control of metastatic lesions in 
limited metastases. The guidelines also include RFA as options for symptomatic patients 
with disseminated metastases. "The guidelines are intentionally nonspecific about this 
group of options, because many different issues are factored into this decision (e.g., patient 
performance status, patient preferences, specific clinical problems from the metastases, 
treatment availability.)" (46). 
4.12. RFA of gastrointestinal stromal tumors 
Pawlik et al at MD Anderson Cancer Center reported a series with 36 non-GIST sarcoma 
patients and 31 GIST patients who received RFA and/or surgical resection of liver 
metastases. (47). When surgical resection was possible, that was the first choice (35 patients). 
RFA was used in combination with surgical resection of the largest lesions in 18 cases. RFA 
was used alone in 13 cases. Those patients treated with RFA alone, or in combination with 
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surgical resection, had a significantly higher rate of recurrence (90.9%) than did patients 
who underwent resection alone (57.1%). However, this difference probably reflects a 
selection bias, since RFA was never used for patients whose tumors were resectable. Patients 
who were treated with RFA either alone or as a combined modality with resection also had 
a shorter disease-free interval (7.4 months) than patients who underwent resection alone 
(18.6 months). Avritscher et al reported three advanced GIST patients whose focal liver 
progression was successfully treated with RFA. The patients remained progression-free at 8, 
15, and 16 months after ablation (48) . 
In an ASCO poster presentation, Dileo et al reported treating 9 patients with percutaneous 
CT-guided RFA for single or limited site(s) of progressing disease (8 liver lesions and 1 soft 
tissue lesion). Thee were no complications from the RFA procedure. With median follow-up 
of 4.2 months (range 1-11 months), all patients had their lesions completely ablated. Five 
patients developed systemic progression, while 4 patients remain stable on continued 
treatment with imatinib (median follow-up 5.8 m). The authors concluded "In this small 
cohort, percutaneous RFA appears to be a safe and effective treatment for localized sites of 
progression. This procedure helps to manage limited IM-resistant GIST. Continuation of 
imatinib to control systemic sites of imatinib-sensitive GIST despite emergence of limited 
clonal resistance can be justified on the basis of this exploratory work." (49) 
Evaluating the evidence about RFA for GIST. RFA appears to be a viable palliative option 
for patients with advanced GIST who develop focal progression of liver or peritoneal 
disease during imatinib therapy and who are not otherwise candidates for surgical 
resection. Alternatively, RFA offers a potentially curative option for patients who exhibit a 
partial response to imatinib and have focal residual disease that is not amenable to surgical 
resection .The guidelines (NCCN, 2010) also recommend the use of RFA for the treatment of 
gastrointestinal stromal tumors with limited progression. Progression is defined as a new 
lesion or increase in tumor size. The NCCN guidelines state that, for limited progressive 
disease that is potentially easily resectable, surgical resection should be considered. Other 
treatment options include RFA or embolization. 
4.13. RFA of malignant biliary obstruction 
In an open-label, pilot study, Steel et al in 2011 examined the safety of endobiliary bipolar 
RFA in patients with malignant biliary obstruction and reported the 90-day biliary patency 
of this novel procedure. Main outcome measures were immediate and 30-day complications 
as well as 90-day stent patency. A total of 22 patients (16 pancreatic, 6 cholangiocarcinoma) 
were includedin this study. Deployment of an RFA catheter was successful in 21 patients. 
Self-expandable metal stents (SEMSs) placement was achieved in all cases of successful RFA 
catheter deployment. One patient failed to demonstrate successful biliary decompression 
after SEMS placement and died within 90 days. All other patients maintained stent patency 
at 30 days. One patient had asymptomatic biochemical pancreatitis, 2 patients required 
percutaneous gallbladder drainage, and 1 patient developed rigors. At 90-day follow-up, 1 
additional patient had died with a patent stent, and 3 patients had occluded biliary stents. 
 
Hyperthermia and Radiology 161 
The authors concluded that endobiliary RFA treatment appears to be safe. They stated that 
randomized studies with prolonged follow-up are needed (50). 
4.14. Role of hyperthermia in treatment of cervical cancer patients 
Today, the technique is a standard treatment for patients with advanced cervical cancer, or 
patients with less advanced cervical cancer that cannot clinically tolerate chemotherapy. It is 
recommended and used as an alternative to the international gold standard of combined 
radiation therapy and cisplatin-based chemotherapy (51). The Dutch Deep Hyperthermia 
Trial, conducted between 1990 and 1996 and published in the Lancet in 2000, was a 
prospective, randomized trial that compared the outcomes of 358 patients with advanced 
bladder, cervical, and rectal tumors. Half of the patients received only radiation therapy and 
the other half received both radiation therapy and hyperthermia. Three-year outcomes 
revealed that hyperthermia improved both pelvic control and overall survival rates, but 
seemed to be most effective for patients with advanced cervical cancer (52). At 36 months, of 
an original cohort of 114 patients with advanced cervical cancer, the 58 patients receiving both 
treatments showed a complete response rate of 83%, compared with 57% for the 56 patients 
who only received radiation therapy. The survival rate was 51% for the combined treatment 
group, compared with 27% for the radiation therapy-only group. Furthermore, hyperthermia 
treatments did not enhance radiation toxicity and were reported to be cost-effective  
However, long-term outcomes (12-year follow-up) was addressed by a follow-up study 
published in 2008 that tracked outcomes for both groups 12 years following treatment. The 
patients who received the combined treatment continued to have significantly better 
outcomes. The outcomes for the combined therapy group remained consistent. At the end of 
the study period, 37% of this group was still alive, compared with 20% who received 
radiation only. Of the combined therapy group, 56% retained pelvic tumor control, 
compared with 37% for the radiation therapy group. Pelvic recurrence developed in 25% of 
the combined therapy group and 31% of the radiation therapy group. Approximately one-
third of both cohorts developed distant metastasis. Both groups experienced the same 
number of grades 3-5 radiation-induced toxicities (53). 
4.15. Radiofrequency ablation therapy for varicose veins 
Venous insufficiency resulting from superficial reflux because of varicose veins is a serious 
problem that usually progresses inexorably if left untreated. When the refluxing circuit involves 
failure of the primary valves at the saphenofemoral junction, treatment options for the patient 
are limited, and early recurrences are the rule rather than the exception. In the historical surgical 
approach, ligation and division of the saphenous trunk and all proximal tributaries are followed 
either by stripping of the vein or by avulsion phlebectomy. Proximal ligation requires a 
substantial incision at the groin crease. Stripping of the vein requires additional incisions at the 
knee or below and is associated with a high incidence of minor surgical complications. Avulsion 
phlebectomy requires multiple 2- to 3-mm incisions along the course of the vein and can cause 
damage to adjacent nerves and lymphatic vessels. Endovenous ablation has replaced stripping 
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and ligation as the technique for elimination of saphenous vein reflux. One of the endovenous 
techniques is a radiofrequency-based procedure. Newer methods of delivery of radiofrequency 
were introduced in 2007. Endovenous procedures are far less invasive than surgery and have 
lower complication rates. The procedure is well tolerated by patients, and it produces good 
cosmetic results. Excellent clinical results are seen at 4-5 years, and the long-term efficacy of the 
procedure is now known with 10 years of experience (54-55).  
The US Food and Drug Administration (FDA) cleared the original radiofrequency endovenous 
procedure in March 1999. Endovenous techniques (endovenous laser therapy, radiofrequency 
ablation, and endovenous foam sclerotherapy) clearly are less invasive and are associated with 
fewer complications compared with more invasive surgical procedures, with comparable or 
greater efficacy. The original radiofrequency endovenous ablation system worked by thermal 
destruction of venous tissues using electrical energy passing through tissue in the form of 
high-frequency alternating current. This current was converted into heat, which causes 
irreversible localized tissue damage. Radiofrequency energy is delivered through a special 
catheter with deployable electrodes at the tip; the electrodes touch the vein walls and deliver 
energy directly into the tissues without coagulating blood. The newest system, called 
ClosureFast, delivers infrared energy to vein walls by directly heating a catheter tip with 
radiofrequency energy. Published results show a high early success rate with a very low 
subsequent recurrence rate up to 10 years after treatment. Early and mid range results are 
comparable to those obtained with other endovenous ablation techniques. The authors’ overall 
experience has been a 90% success rate, with rare patients requiring a repeat procedure in 6-12 
months. Overall efficacy and lower morbidity have resulted in endovenous ablation 
techniques replacing surgical stripping. Patient satisfaction is high and downtime is minimal, 
with 95% of patients reporting they would recommend the procedure to a friend (56-58). 
 
Figure 5. A diagram shows the technique of RFA for varicose veins .A. The catheter is inserted and 
advanced into the diseases vein through a small incision into the diseased vein under ultrasound 
guidance. B Then laser or radiofrequency energy is applied to the lining of the vein, heating and 
shrinking the vein walls, causing them to seal and as the catheter withdrawn the vein is closed  
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4.16. Catheter ablation for paroxysmal atrial fibrillation 
Other diseases where ablation is used include cardiac catheter thermal ablation is now 
standard of care for a variety of cardiac arrhythmia types (irregular heart beat rhythm). 
Techniques are directed at cauterizing areas of high irritability that give rise to frequent ectopy 
and trigger paroxysmal atrial fibrillation (PAF), or cauterisation of the substrate that maintains 
PAF, (predominantly left atrial tissue), or both. Usually this is done with radiofrequency 
energy delivered percutaneously by steerable catheters. In the UK, recent Guidance from 
NICE approved catheter ablation for PAF on the NHS for patients who have failed treatment 
with two antiarrhythmic drugs. Similar guidelines exist in the USA. Success rates of 70-80% 
can be achieved, with multiple procedures being needed in many cases. RFCA for PAF carries 
significant risks. These are; stroke (<1%), cardiac tamponade (2-6%), pulmonary vein stenosis 
(0.5-1%), a small risk of arteriovenous fistula (<0.5%), and a very small but important risk of 
oesophago-atrial fistula. In older patients, (>70 years), patients with structural heart disease and 
patients with persistent or prolonged AF, there is significantly less chance of success with 
RFCA. Recently an electro-anatomic mapping systems" (a form of mini-"GPS", or "Sat-Nav" 
system), are becoming increasingly sophisticated at telling an electrophysiologist exactly where 
a catheter is within the heart, and exactly where anatomical structures are located relative to it. 
This is important for avoiding complications. A CT Scan or MRI scan of heart chambers is 
useful for obtaining the detailed anatomy of the heart for RFCA procedures (59-61). 
RFA of the AV-junction followed by implantation of a pacemaker provides good control of 
symptoms, reduced drug and healthcare consumption, and reduced hospital admissions. 
However, AV-junctional ablation is not reversible, and allows atrial fibrillation to continue, 
albeit without allowing it to produce rapid, irregular ventricular rates, so that patients may 
be unaware of being in PAF. RFA of the AV-junction followed by implantation of a 
pacemaker is increasingly reserved for patients with established/chronic AF in whom 
ventricular rate-control cannot be achieved with AV-nodal blocking drugs. In these patients 
AF persists in spite of treatment anyway, and RFA of the AV-junction with permanent 
pacing can give excellent symptom control (NICE 2006) (62). 
5. Combination of hyperthermia with radiotherapy in treatment of cancer 
Hyperthermia is a heat cancer treatment FDA approved in combination with low-dose-
radiation, applied to tumors, raising tumor temperature to about 42.5°C (108°F) for about 45 to 
60 minutes. Heat improves blood circulation and makes tumor cells more susceptible to the 
low-dose- radiation therapy, killing them more efficiently and quickly. Hyperthermia can be 
compared with an artificial fever that attacks cancer cells. Starting in the late 1970s, a major 
focus of many researchers was on achieving focal, cytotoxic temperatures of 42-45 oC within 
tumors, a strategy which can sensitize tumors to radiation and/or chemotherapy. Remarkable 
progress in engineering and physics over the past 20 years has led to the implementation of 
clinical trials that are revealing the true potential of this strategy. Over the past decade, positive 
clinical data has emerged from trials utilizing HT in the treatment of recurrent chest wall breast 
cancer, melanoma, esophageal cancer, locally advanced head and neck cancer, locally advanced 
 Hyperthermia 164 
cervix cancer and gliomas. 1) Hyperthermia increases perfusion and oxygenation of neoplastic 
hypoxic cells, which are three times more resistant to ionizing radiation than normal cells. 
Consequently, the action of radiotherapy becomes 1.5-5 times more efficient. Hyperthermia has 
a direct cytotoxic action on cancer: due to the pathologic blood vessels, the thermal elevation 
persists inside the tumor, whereas neighboring normal tissues, adequately perfused, are cooled: 
at 43 °C, normal cells are not damaged, whereas tumor cells are damaged at the cell nucleus, 
plasmatic membrane and cytoskeleton, up to apoptosis. Hyperthermia acts mostly at an acid 
pH and in the S phase of the cell cycle, when cells are radioresistant. This means that 
radiotherapy and hyperthermia are complementary in their action: radiotherapy forms free 
radicals, which damage the DNA of tumor cells, whereas hyperthermia inhibits its reparation. 
2) Hyperthermic inhibition of repairing radiation damage has been suggested as an essential 
factor causing the synergistic cell-killing effect of X-rays and hyperthermia. Heating cells before 
X-irradiation has been shown to inhibit the repair of DNA strand breaks as well as the excision 
of base damage1. There are several DNA repair pathways involved in restoration of damage 
after ionizing irradiation and the kinetics of all of them are affected by heat shock. However, 
this does not imply that the inhibition of each of these pathways is relevant to the effect of heat 
on cellular radiosensitivity. Data reported by Kampinga et al showed that thermal inhibition of 
the non-homologous end-joining pathway plays a role in heat radiosensitization. Furthermore, 
limited data suggest that the homologous recombination pathway may not be a major heat 
target. The inhibition of base-excision damage repair could be, by deduction, the crucial step in 
the mechanism of radiosensitization by heat (63). 3) Hyperthermia enhances the sensitivity of 
cells to radiation and drugs and this sensitization is not directly related to altered heat-shock 
proteins (HSP) expression. Elevating HSP prior to heating makes cells thermo- tolerant and 
altering their expression will affect the extent of thermal action because the HSP will 
attenuate the heat-induced protein damage, responsible for radiation and drug sensitization. 
Nuclear protein damage is considered to be responsible for hyperthermic effects on DNA 
repair, especially base-excision damage repair (64). 
In an effort to provide a clearer picture of the interaction between hyperthermia and 
radiation, asynchronous CHO cell survivals for a matrix of doses of radiation and 
hyperthermia were determined. The survival matrix was then analyzed by fitting a survival 
function that was the product of survivals due to hyperthermia alone, to radiation alone and 
to the interaction of hyperthermia and radiation. This survival function is an expression for 
the survival surface, a surface in the space defined by the three axes of logarithm of cell 
survival, hyperthermia dose and radiation dose. The survival surface is a three dimensional 
extension of the two-dimensional survival curve (65). 
The two principal rationales for applying hyperthermia in cancer therapy are that: (a) the S 
phase, which is relatively radioresistant, is the most sensitive phase to hyperthermia, and can 
be selectively radiosensitized by combining hyperthermia with x-irradiation; the cycling tumor 
cells in S phase which would normally survive an x-ray dose could thus be killed by subjecting 
these cells to hyperthermia; and (b) the relatively radioresistant hypoxic cells in the tumor may 
be selectively destroyed by combinations of hyperthermia and x-irradiation. Both of these 
rationales have been mentioned as reasons for using high LET irradiation in cancer therapy; 
therefore where such irradiation may be of use, hyperthermia may also be advantageous. 
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It is a heat cancer treatment FDA approved in combination with low-dose-radiation, 
applied to tumors, raising tumor temperature to about 42.5°C (108°F) for about 45 to 60 
minutes. Heat improves blood circulation and makes tumor cells more susceptible to the 
low-dose- radiation therapy, killing them more efficiently and quickly As a result of these 
and other clinical applications, combined with a rapidly expanding research base, interest in 
thermal medicine is rapidly growing, attracting the attention of laboratory and clinical 
researchers, physicians, engineers, physicists and biotechnologists. 
6. Rationale for chemotherapy and hyperthermia association 
Hyperthermia can also be used to activate cytotoxic effects of chemotherapy within tumors, 
thereby sparing normal tissue, when the drugs are encapsulated in thermally sensitive 
nanoparticles. Hyperthermic drug sensitization can be seen for several anti-cancer drugs, in 
particular alkylating agents. The combined action between heat and drugs arises from 
multiple events such as drug accumulation, drug detoxification pathways and repair of 
drug-induced DNA adducts. Cells with acquired drug resistance can be made responsive to 
the same drugs again by combining drugs with heat. Hyperthermia, which increases tumor 
tissue perfusion, facilitates the absorption of chemotherapeutic drugs through cell 
membrane. The heat accelerates chemical reactions, so that chemotherapy becomes more 
effective, without being more toxic. Hyperthermia allows the response of tumors resistant to 
various chemotherapeutic drugs: doxorubicin, cisplatin, bleomycin, mitomycin c, 
nitrosoureas, cyclophosphamide. Use of liposomes, including adriamycin (Caelyx®) 
administered i.v., hyperthermia fuses and frees their content inside the heated tumor bed, 
thus obtaining a target chemotherapy, with reduction of side effects. 
On March 18, 2010, the Celsion Corporation (http://www.celsion.com, accessed 17 November 
2010) announced that an abstract about the phase I/II trial of ThermoDox® in recurrent chest 
wall cancer has been accepted for presentation at the American Society of Clinical Oncology 
(ASCO) 2010 Annual Meeting. The abstract presents the background, rationale and design of 
the DIGNITY study which is ongoing and evaluating ThermoDox® in combination with 
hyperthermia in women with recurrent breast cancer on their chest wall (66).  
In a separate trial with a similar design being conducted at Duke University Medical Center, 
researchers are reporting convincing evidence of clinical activity. The DIGNITY clinical trial 
is a phase I/II, open label, dose- escalating trial to evaluate the safety and efficacy of 
ThermoDox® with hyperthermia for the treatment of recurrent chest wall breast cancer, an 
aggressive form of cancer with a poor prognosis and limited treatment options. The primary 
end point in the DIGNITY trial is durable complete local response at the tumor site. Once 
the safe dose is determined, Celsion intends to enroll up to 100 patients to establish efficacy. 
The results from the DIGNITY trial are expected to build on the promising data from the 
phase I dose-escalation study currently being conducted at Duke University Medical Center. 
ThermoDox® has also demonstrated evidence of efficacy in a phase I study for primary liver 
cancer. Celsion has been granted FDA orphan drug designation for ThermoDox® and is 
conducting a pivotal 600 patient global phase III study in primary liver cancer under an 
FDA special protocol assessment, thus obtaining a target chemotherapy, with reduction of 
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side effects. It has been demonstrated that hyperthermia also has an anti-angiogenic action 
and an immunotherapeutic role, due to thermal shock proteins, which are produced by 
stressed tumor cells. Finally, hyperthermia substains the action of genic therapy (67). 
The immunotherapeutic role of hyperthermia is not yet completely understood. Especially, 
the effects on natural killer (NK) cell cytotoxicity against tumor cell targets have not been 
fully demonstrated. At treatment temperatures above 40 °C, both enhancing and inhibitory 
effects of cytotoxic activity of NK cells against tumor cells have been reported. In particular, 
an enhancement of human NK cytotoxicity against tumor cell targets has been 
demonstrated using a temperature of 39.5 °C10. Data in the literature indicate a strong 
potential for heat-induced enhancement of NK cell activity in mediating the improved 
clinical response. A better understanding in this field should be achieved in order to 
maximize the clinical benefits obtained by using hyperthermia for cancer therapy (68). 
7. Heat-activated drug delivery  
An exciting new generation of clinical trials is now harnessing drug-containing thermosensitive 
liposomes, and other nanoparticle drug carriers, that release contained chemotherapy agents 
upon heating above ~40 °C. Combined with localized heating methods as described above, this 
allows for targeted chemotherapy delivery to tumors. Thermal ablation or hyperthermia can be 
combined with heat-activated drug carriers to selectively deposit chemotherapy in the heated 
area. Initial clinical trial results suggest patient benefits from this combination and thus there is 
considerable excitement among members of our Society in this approach. 
8. Conclusions 
Hyperthermia, thanks to the improved systems for achieving an optimal distribution of heat 
inside the tumor and precise and noninvasive thermometry, is today an important treatment 
modality in the treatment of cancer, and its results are strongly supported by criteria of 
evidence-based medicine. Hyperthermia is an important treatment modality in cancer 
treatment and its results are strongly supported by criteria of evidence-based medicine. 
Hyperthermia is a therapeutic modality that, employing nonionizing radiations, can be used 
not only by radiation oncologists but also by clinical oncologists. Its addition to 
radiotherapy with or without chemotherapy is important when it is necessary to treat 
advanced or high-risk tumors, or to retreat a relapse in a pre-irradiated area. Hyperthermia 
appears to be the fourth pillar besides surgery, radiotherapy and chemotherapy.   
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